Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-BCMA in r/r Plasma Cell Neoplasms
NCT07085559Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of metabolically armed BCMA CAR-T cells in multiple myeloma (MM), plasma cell leukemia (PCL) and amyloid light chain amyloidosis, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Maximum Tolerated Dose at 35 days and Adverse Events at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
metabolically armed BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07085559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085559.